IAM-C1 / Iambic Therap - LARVOL DELTA

IAM-C1, a potent and selective dual CDK2/CDK4 inhibitor, demonstrates robust antitumor activity and a favorable preclinical tolerability profile (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Oncology

Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference (Businesswire) - "Dr. Miller will detail progress and anticipated milestones for Iambic’s emerging pipeline of development candidates, as well as advances to its AI drug discovery platform. The Company’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs."

Clinical • Oncology • Solid Tumor

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA (Businesswire) - "Funding will Support Continued AI Platform Innovations and Advancement of Multiple Candidates into Clinical Development, Including IAM-H1, a Selective Brain-Penetrant HER2 Inhibitor, and IAM-C1, a Selective Dual CDK2/4 Inhibitor."

Commercial • Oncology • Solid Tumor